ArticleMikrochimica acta2026
Built-in thiol mesoporous carbon immunosensor to detect carcinoembryonic antigen in human serum.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A label-free electrochemical immunosensor for carcinoembryonic antigens (CEA) detection is reported based on a built-in thiol-mesoporous carbon architecture. The material was functionalized with 3-maleimidepropionic acid to immobilize anti-CEA antibodies. The immunosensor was characterized using field-emission scanning electron microscopy, X-ray photoelectron spectroscopy, cyclic voltammetry, and electrochemical impedance spectroscopy. Biorecognition events were monitored by differential pulse voltammetry, with current intensity dependent on protein concentration. The device exhibited a linear range of 1–10 ng mL-1 for CEA, with a clinically relevant limit of detection of 1.02 ng mL-1. The immunosensor successfully detected CEA in human serum samples, with results comparable to those obtained by a standard spectrophotometric method. This platform has proven to be a promising alternative for the prognosis and management of patients with colorectal cancer, as well as having significant potential for point-of-care diagnosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.